{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T02:49:38Z","timestamp":1768963778976,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The patient\u2019s perspective is increasingly relevant in health decision making. In daily practice, care of patients with migraine should include evaluation of their satisfaction with acute and preventive treatments, the interference with daily living, as well as with the care received by the healthcare team. The aim was to develop and validate a novel specific self-reported patient-reported-experience measure (PREM) in Spanish (Spain), to ascertain satisfaction with migraine treatment; the MISAT-Q questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>A multicenter, crosssectional, non-interventional study was conducted between June 2023 and March 2024 in headache units in Spain. Patients with migraine currently receiving treatment were included. A 35-items preliminary instrument was developed after literature review and cognitive debriefing with experts and patients. Three samples were used: a) 23 patients to assess feasibility\/pertinence of items; b) 158 patients for item reduction; and c) 209 patients for validation of PREM. Measures for concept validity included Patient Global Impression of change (PGI), Headache Impact Scale-6 items (HIT-6), and Health-Related Quality-of-life (EQ-5D-3\u2009L). Feasibility, reliability and validity (content, discriminant, construct, and concurrent) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Feasibility: face value (good acceptance to answer the questionnaire), administration time (below 10\u2009minutes), floor and ceiling effects (below 40% in any extreme response category), percentage of missing values in each item (below 20%) was found in the validation sample. Factor analysis item reduction resulted in a 22-item questionnaire with 7 dimensions: undesirable side effects, treatment effectiveness in crisis and in prevention, convenience-of-use, impact on daily activities, medical care, and global satisfaction, supported with confirmatory factor analysis: CFI\u2009=\u20090.983; TLI\u2009=\u20090.980; \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \/df\u2009=\u20091.808; RMSEA\u2009=\u20090.075. Reliability was high: Cronbach\u2019s alpha\u2009=\u20090.90 and intraclass-correlation coefficient\u2009=\u20090.95. Dimensions of questionnaire showed significant and moderate convergent correlations with the overall score (0.58\u20130.68,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Concurrent validity with HIT-6 showed correlation\u2019s coefficients ranging from \u22120.19 to \u22120.48 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01 in all cases, except medical care) and with EQ-5D-3\u2009L (correlations from 0.17 to 0.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 in all cases, except medical care). Differences in satisfaction were found according with migraine severity (F\u2009=\u20096.73,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), as well as in HIT-6 scores (F\u2009=\u20098.20,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.002). MISAT-Q discriminated overall satisfaction between patients with worse, no change and better change with treatment (F\u2009=\u200915.85;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The MISAT-Q questionnaire is a well-accepted, reliable and valid measure of migraine treatment satisfaction in Spanish. Responsiveness attribute needs to be explored. This novel PREM may facilitate clinicians when making health decision in the treatment management of patients with migraine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-025-00979-x","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:16:38Z","timestamp":1765811798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a patient-reported-experience measure to ascertain treatment satisfaction in migraine: the MISAT-Q questionnaire"],"prefix":"10.1186","volume":"10","author":[{"given":"Ana B.","family":"Gago-Veiga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"D\u00edaz-de-Ter\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Heredia-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Armada-Pel\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlota","family":"Moya-Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Soto-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Rejas-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1.","family":"Ruiz-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"979_CR1","doi-asserted-by":"publisher","unstructured":"Dodick DW (2018) Migraine. Lancet, vol 391. London, England, pp 1315\u20131330. https:\/\/doi.org\/10.1016\/S0140-6736(18)30478-1","DOI":"10.1016\/S0140-6736(18)30478-1"},{"key":"979_CR2","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Azor\u00edn D, Moya-Alarc\u00f3n C, Armada B, S\u00e1nchez Del R\u00edo M (2024) Societal and economic burden of migraine in Spain: results from the 2020 National health and wellness survey. J Headache Pain 25:38. https:\/\/doi.org\/10.1186\/s10194-024-01740-3","DOI":"10.1186\/s10194-024-01740-3"},{"key":"979_CR3","doi-asserted-by":"publisher","first-page":"S0025\u20136196(16)0","DOI":"10.1016\/j.mayocp.2016.02.013","volume":"25","author":"DC Buse","year":"2016","unstructured":"Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Adams AM et al (2016) Impact of migraine on the family: perspectives of people with migraine and their Spouse\/Domestic partner in the CaMEO study. Mayo Clin Proc 25:S0025\u20136196(16)00126\u20139. https:\/\/doi.org\/10.1016\/j.mayocp.2016.02.013","journal-title":"Mayo Clin Proc"},{"key":"979_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBD 2016 Headache Collaborators","year":"2018","unstructured":"GBD 2016 Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990-2016. A systematic analysis for the global burden of disease study 2016. Lancet Neurol 17:954\u2013976. https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"key":"979_CR5","doi-asserted-by":"publisher","unstructured":"Evers S, Dell\u2019agnello G, Novick D, Gonderten HS, Panni T, Pascual J (2024) Acute treatment patterns, migraine burden, and healthcare resource use in people with migraine: results from the overcome (eu) observational study. Pain Ther 13:589\u2013607. https:\/\/doi.org\/10.1007\/s40122-024-00589-3","DOI":"10.1007\/s40122-024-00589-3"},{"key":"979_CR6","doi-asserted-by":"publisher","unstructured":"Pascual J, N\u00fa\u00f1ez M, Panni T, D\u00edaz-Cerezo S, Novick D, Ciudad A (2023) Burden and unmet needs in migraine patients: results from the overcome (Spain) study. Pain Ther 12:1209\u20131220. https:\/\/doi.org\/10.1007\/s40122-023-00538-6","DOI":"10.1007\/s40122-023-00538-6"},{"key":"979_CR7","doi-asserted-by":"publisher","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x","DOI":"10.1186\/s10194-022-01431-x"},{"key":"979_CR8","doi-asserted-by":"publisher","unstructured":"Pozo-Rosich P, Carmo M, Mu\u00f1iz A, Armada B, Moya-Alarc\u00f3n C, Pascual J (2024) Migraine treatment: quo vadis? real-world data study (2015-2022) in Spain. BMC Neurol 24:107. https:\/\/doi.org\/10.1186\/s12883-024-03600-8","DOI":"10.1186\/s12883-024-03600-8"},{"key":"979_CR9","doi-asserted-by":"publisher","unstructured":"Pascual J, Panni T, Dell\u2019agnello G, Gonderten S, Novick D, Evers S (2023) Preventive treatment patterns and treatment satisfaction in migraine: results of the overcome (eu) study. J Head Pain 24(1):88. https:\/\/doi.org\/10.1186\/s10194-023-01623-z","DOI":"10.1186\/s10194-023-01623-z"},{"issue":"4","key":"979_CR10","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s40120-023-00495-4","volume":"12","author":"J Porta-Etessam","year":"2023","unstructured":"Porta-Etessam J, Santos-Lasaosa S, Rodr\u00edguez-Vico J, N\u00fa\u00f1ez M, Ciudad A, D\u00edaz-Cerezo S et al (2023) Evaluating the impact of a training program in shared decision-making for neurologists treating people with migraine. Neurol Ther 12(4):1319\u20131334. https:\/\/doi.org\/10.1007\/s40120-023-00495-4","journal-title":"Neurol Ther"},{"key":"979_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s10194-021-01366-9","volume":"22","author":"A Alpuente","year":"2021","unstructured":"Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P (2021) In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain 22:151. https:\/\/doi.org\/10.1186\/s10194-021-01366-9","journal-title":"J Headache Pain"},{"issue":"5","key":"979_CR12","doi-asserted-by":"publisher","first-page":"e16187","DOI":"10.1016\/j.heliyon.2023.e16187","volume":"9","author":"PY Dikmen","year":"2023","unstructured":"Dikmen PY, Ozge A, Martelletti P (2023) The use of clinical scales and PROMs in headache disorders and migraine, summarizing their dissemination and operationalization. Heliyon 9(5):e16187. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16187","journal-title":"Heliyon"},{"key":"979_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/a:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6\u2122. Qual Life Res 12:963\u2013974. https:\/\/doi.org\/10.1023\/a:1026119331193","journal-title":"Qual Life Res"},{"issue":"suppl_1","key":"979_CR14","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/wnl.56.suppl_1.s20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the migraine disability assessment (MIDAS) questionnaire to assess headache-related disability. Neurology 56(suppl_1):S20\u2013S28. https:\/\/doi.org\/10.1212\/wnl.56.suppl_1.s20","journal-title":"Neurology"},{"key":"979_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1526-4610.2011.01997.x","volume":"52","author":"CL Bagley","year":"2012","unstructured":"Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J et al (2012) Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache 52:409\u2013421. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01997.x","journal-title":"Headache"},{"issue":"10","key":"979_CR16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1046\/j.1526-4610.2002.02230.x","volume":"42","author":"ML Chatterton","year":"2002","unstructured":"Chatterton ML, Lofland JH, Shechter A, Curtice WS, Hu XH, Lenow J et al (2002) Reliability and validity of the migraine therapy assessment questionnaire. Headache 42(10):1006\u20131015. https:\/\/doi.org\/10.1046\/j.1526-4610.2002.02230.x","journal-title":"Headache"},{"issue":"5","key":"979_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1046\/J.1524-4733.2002.55120.x","volume":"5","author":"KH Davis","year":"2002","unstructured":"Davis KH, Black L, Sleath B (2002) Validation of the patient perception of migraine questionnaire. Value Health 5(5):422\u2013430. https:\/\/doi.org\/10.1046\/J.1524-4733.2002.55120.x","journal-title":"Value Health"},{"key":"979_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1526-4610.2006.00289.x","volume":"46","author":"DA Revicki","year":"2006","unstructured":"Revicki DA, Kimel M, Beusterien K, Kwong JW, Varner JA, Ames MH et al (2006) Validation of the revised patient perception of migraine questionnaire: measuring satisfaction with acute migraine treatment. Headache 46:240\u2013252. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00289.x","journal-title":"Headache"},{"issue":"11","key":"979_CR19","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1016\/s0149-2918(03)80345-4","volume":"25","author":"DL Patrick","year":"2003","unstructured":"Patrick DL, Martin ML, Bushnell DM, Pesa J (2003) Measuring satisfaction with migraine treatment: expectations, importance, outcomes, and global ratings. Clin Ther 25(11):2920\u20132935. https:\/\/doi.org\/10.1016\/s0149-2918(03)80345-4","journal-title":"Clin Ther"},{"key":"979_CR20","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s11136-021-02822-4","volume":"30","author":"JJ Gagnier","year":"2021","unstructured":"Gagnier JJ, Lai J, Mokkink LB, Terwee CB (2021) COSMIN reporting guideline for studies on measurement properties of patient-reported outcome measures. Qual Life Res 30(8):2197\u20132218. https:\/\/doi.org\/10.1007\/s11136-021-02822-4","journal-title":"Qual Life Res"},{"key":"979_CR21","volume-title":"Applied factor analysis","author":"RJ Rummel","year":"1970","unstructured":"Rummel RJ (1970) Applied factor analysis. Northwestern University Press, Evanston"},{"key":"979_CR22","doi-asserted-by":"publisher","first-page":"532560","DOI":"10.1207\/s15327752jpa6803_5","volume":"68","author":"RL Gorsuch","year":"1997","unstructured":"Gorsuch RL (1997) Exploratory factor analysis: its role in item analysis. J Pers Assess 68:532560. https:\/\/doi.org\/10.1207\/s15327752jpa6803_5","journal-title":"J Pers Assess"},{"key":"979_CR23","volume-title":"Teor\u00eda Psicom\u00e9trica","author":"JC Nunnally","year":"1995","unstructured":"Nunnally JC, Bernstein IJ (1995) Teor\u00eda Psicom\u00e9trica. McGrawHill, M\u00e9xico"},{"issue":"5","key":"979_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1524-4733.2008.00323.x","volume":"11","author":"MA Ruiz","year":"2008","unstructured":"Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL (2008) Development and validation of the \u201ctreatment satisfaction with medicines questionnaire\u201d. (SATMED-Q) Value Health 11(5):913\u2013926. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00323.x","journal-title":"(SATMED-Q) Value Health"},{"key":"979_CR25","first-page":"4960","volume":"2","author":"RJ Rovinelli","year":"1977","unstructured":"Rovinelli RJ, Hambleton RK (1977) On the use of content specialists in the assessment of criterionreferenced test item validity. Dutch J Educ Res 2:4960","journal-title":"Dutch J Educ Res"},{"key":"979_CR26","volume-title":"Multiple factor analysis","author":"LL Thrustone","year":"1947","unstructured":"Thrustone LL (1947) Multiple factor analysis. University of Chicago Press, Chicago"},{"key":"979_CR27","doi-asserted-by":"crossref","unstructured":"Devlin N, Parkin D, Janssen B (2020; 2020) Methods for analyzing and reporting EQ-5D data [internet]. Chapter 1. An Introduction to EQ-5D Instruments and Their Applications. Cham (CH). Available from: Springer. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK565680\/10.1007\/978-3-030-47622-9_1","DOI":"10.1007\/978-3-030-47622-9_1"},{"issue":"12","key":"979_CR28","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1016\/j.jaip.2023.08.046","volume":"11","author":"K Rhatigan","year":"2023","unstructured":"Rhatigan K, Hirons B, Kesavan H, Turner RD, Ebelthite C, Hull JH et al (2023) Patient global impression of severity scale in chronic cough: validation and formulation of symptom severity categories. J Allergy Clin Immunol Pract 11(12):3706\u20133712.e1. https:\/\/doi.org\/10.1016\/j.jaip.2023.08.046","journal-title":"J Allergy Clin Immunol Pract"},{"key":"979_CR29","doi-asserted-by":"publisher","unstructured":"Schreiber JB, Nora A, Stage FK, Barlow EA, King J (2006) Reporting structural equation modeling and confirmatory factor analysis results: a review. J Educ Res 99(6):323\u2013338. https:\/\/doi.org\/10.3200\/JOER.99.6.323-338","DOI":"10.3200\/JOER.99.6.323-338"},{"issue":"4","key":"979_CR30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jclinepi.2007.05.011","volume":"61","author":"J Rejas","year":"2008","unstructured":"Rejas J, Pardo A, Ruiz MA (2008) Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patient-reported outcomes measures. J Clin Epidemiol 61(4):350\u2013356. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.05.011","journal-title":"J Clin Epidemiol"},{"key":"979_CR31","first-page":"107","volume":"13","author":"MA Ruiz","year":"1993","unstructured":"Ruiz MA, San Mart\u00edn R (1993) Determinaci\u00f3n del n\u00famero de autovalores mayores que la unidad en el An\u00e1lisis Imagen con el SPSS. Psicol\u00f3gica 13:107\u2013112","journal-title":"Psicol\u00f3gica"},{"key":"979_CR32","doi-asserted-by":"publisher","unstructured":"Velicer WF (1976) Determining the number of components from the matrix of partial correlations. Psychometrika 41:321\u2013327. https:\/\/doi.org\/10.1007\/BF02293557","DOI":"10.1007\/BF02293557"},{"key":"979_CR33","first-page":"543550","volume":"4","author":"MA Ruiz","year":"1992","unstructured":"Ruiz MA, San Mart\u00edn R (1992) Una simulaci\u00f3n sobre el comportamiento de la regla K1 en la estimaci\u00f3n del n\u00famero de factores. Psicothema 4:543550","journal-title":"Psicothema"},{"key":"979_CR34","doi-asserted-by":"publisher","first-page":"432442","DOI":"10.1037\/0033-2909.99.3.432","volume":"3","author":"WR Zwick","year":"1986","unstructured":"Zwick WR, Velicer WF (1986) A comparison of five rules for determining the number of components to retain. Psych Bull 3:432442. https:\/\/doi.org\/10.1037\/0033-2909.99.3.432","journal-title":"Psych Bull"},{"key":"979_CR35","doi-asserted-by":"publisher","unstructured":"Gorsuch RL (1997) New procedures for extension analysis in exploratory factor analysis. Educ Psych Meas 57:725740. https:\/\/doi.org\/10.1177\/0013164497057005001","DOI":"10.1177\/0013164497057005001"},{"key":"979_CR36","doi-asserted-by":"publisher","unstructured":"Russell D (2002) In search of underlying dimensions: the use (and abuse) of factor analysis in personality and social psychology bulletin. Pers Soc Psych Bull 28:16291646. https:\/\/doi.org\/10.1177\/014616702237645","DOI":"10.1177\/014616702237645"},{"key":"979_CR37","unstructured":"Willke RJ (2008) Measuring the value of treatment to patients: patient reported outcomes in drug development. Am Health Drug Benefits 1(1):34\u201340"},{"issue":"Suppl. 1","key":"979_CR38","doi-asserted-by":"publisher","first-page":"S2S5","DOI":"10.1111\/j.1524-4733.2005.00068.x","volume":"8","author":"WR Lenderking","year":"2005","unstructured":"Lenderking WR (2005) Brief reflections on treatment satisfaction. Value Health 8(Suppl. 1):S2S5. https:\/\/doi.org\/10.1111\/j.1524-4733.2005.00068.x","journal-title":"Value Health"},{"issue":"1","key":"979_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jval.2022.10.005","volume":"26","author":"A M\u00fchlbacher","year":"2023","unstructured":"M\u00fchlbacher A, Stolk E (2023) Patient-reported satisfaction, experiences, and preferences: same but different? Value Health 26(1):1\u20133. https:\/\/doi.org\/10.1016\/j.jval.2022.10.005","journal-title":"Value Health"},{"issue":"1","key":"979_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society (2019) The American headache society position statement on integrating New migraine treatments into clinical practice. Headache 59(1):1\u201318. https:\/\/doi.org\/10.1111\/head.13456","journal-title":"Headache"},{"issue":"4","key":"979_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644\u2013655. https:\/\/doi.org\/10.1111\/head.12055","journal-title":"Headache"},{"key":"979_CR42","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/head.13766","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Lipton RB, Ailani J, Singh RBH, Shewale AR, Zhao S et al (2020) Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, achieve I and II. Headache 60:686\u2013700. https:\/\/doi.org\/10.1111\/head.13766","journal-title":"Headache"},{"key":"979_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2288-11-142","volume":"11","author":"J Rejas","year":"2011","unstructured":"Rejas J, Ruiz MA, Pardo A, Soto J (2011) Minimally important difference of the treatment satisfaction with medicines questionnaire (SATMED-Q). BMC Med Res Methodol 11:142. https:\/\/doi.org\/10.1186\/1471-2288-11-142","journal-title":"BMC Med Res Methodol"},{"key":"979_CR44","doi-asserted-by":"publisher","DOI":"10.4324\/9781410601087","volume-title":"Test theory: a unified treatment","author":"RP McDonald","year":"2013","unstructured":"McDonald RP (2013) Test theory: a unified treatment. Psychology press, NY, NY"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00979-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00979-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00979-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:31:21Z","timestamp":1768919481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-025-00979-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00979-x","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of Good Clinical Practice and Good Laboratory Practice as referenced in the International Council for Harmonization guidelines, as well as all applicable regulations, including any institutional review board requirements relevant to clinical studies. The study also complied with the recommendations in the most recent version of the Declaration of Helsinki. Participants provided written informed consent before any study-related procedures were undertaken. The protocol was approved by the institutional review board of Hospital Universitario de La Princesa, Madrid (Spain), and the Clinical Research Ethics Committee of Universidad Aut\u00f3noma de Madrid, Spain (register code CEI-131- 2722).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors ABGV, NGG, JDT and PHR were the study coordinators and received research support and honoraria from Pfizer S.L.U. ABGV has received honoraria for conferences and\/or advisory boards from Lilly, Novartis, TEVA, Lundbeck, Abbvie and Almirall. NGG has received honoraria for conferences and\/or advisory boards from Lilly, Novartis, TEVA, Lundbeck, Abbvie. JDT has received honoraria for conferences and\/or advisory boards from Lilly, Novartis, TEVA, Lundbeck, Abbvie. PHR has received honoraria of Lundbeck, Novartis, Abbvie and TEVA. MARD is employee of Universidad Aut\u00f3noma de Madrid which received funding from Pfizer S.L.U. CMA and BAP are employees of Pfizer S.L.U. JSA was employee of Pfizer S.L.U. when the study was initiated. JRG was specialist consultant without honoraria from Pfizer S.L.U.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}